JPH0149129B2 - - Google Patents
Info
- Publication number
- JPH0149129B2 JPH0149129B2 JP56204135A JP20413581A JPH0149129B2 JP H0149129 B2 JPH0149129 B2 JP H0149129B2 JP 56204135 A JP56204135 A JP 56204135A JP 20413581 A JP20413581 A JP 20413581A JP H0149129 B2 JPH0149129 B2 JP H0149129B2
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- blood
- pantethine
- lysolecithin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000032839 leukemia Diseases 0.000 claims description 30
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 16
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 16
- 229960000903 pantethine Drugs 0.000 claims description 16
- 235000008975 pantethine Nutrition 0.000 claims description 16
- 239000011581 pantethine Substances 0.000 claims description 16
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000010836 blood and blood product Substances 0.000 claims description 4
- 229940125691 blood product Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56204135A JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56204135A JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58105922A JPS58105922A (ja) | 1983-06-24 |
| JPH0149129B2 true JPH0149129B2 (de) | 1989-10-23 |
Family
ID=16485410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56204135A Granted JPS58105922A (ja) | 1981-12-17 | 1981-12-17 | 白血病治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58105922A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108136020A (zh) * | 2015-09-29 | 2018-06-08 | 国立大学法人大阪大学 | 白细胞浸润促进剂和肿瘤免疫活化剂 |
-
1981
- 1981-12-17 JP JP56204135A patent/JPS58105922A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58105922A (ja) | 1983-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4824669A (en) | Formulations of coenzyme Q10 for intravenous use | |
| Tripathi | Essentials of pharmacology for dentistry | |
| JPH0222229A (ja) | 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤 | |
| Pasquier et al. | “Hemicrania continua”: the first bilateral case? | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| EP2969001A1 (de) | Verwendung von levocetirizin und montelukast bei der behandlung von anaphylaxe | |
| JPH04295424A (ja) | 昏睡治療のためのアセチル−ｌ−カルニチンおよび医薬組成物 | |
| EP0055118A1 (de) | Behandlung von Arthritis | |
| Gupta et al. | Intermittent short duration therapy with fluconazole is effective for tinea capitis | |
| Roberts et al. | Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy | |
| EP0609701A1 (de) | L-Cystein, L-Cystin oder L-Glutamin als zusätzliches Arzneimittel zur Behandlung des Immundefizienssyndroms | |
| US3636202A (en) | Treatment of rheumatoid arthritis and related diseases | |
| AU2402399A (en) | A therapeutic agent for ischemic diseases | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| JPH0149129B2 (de) | ||
| JPH045231A (ja) | 慢性痛用鎮痛剤 | |
| Karatieieva et al. | Treatment of pyoinflammatory complications with individually selected ozone dose in patients with diabetes | |
| Epstein | Synthetic antimalarial drug therapy in lupus erythematosus and polymorphous light eruptions | |
| Smith et al. | Results of hemodialysis & hemoperfusion in the treatment of acute arsenic ingestion | |
| Simon et al. | Administration of obidoxime tablets to man: plasma levels and side reactions | |
| Parkes et al. | Acute nitrobenzene poisoning with transient amino-aciduria | |
| RU2253460C1 (ru) | Способ лечения туберкулеза легких | |
| JPH0251405B2 (de) | ||
| US5277903A (en) | Use of TNF and LT for the preparation of drugs | |
| Kramer | The management of postherpetic neuralgia with chlorprothixene |